Novo Nordisk A/S, of Bagsværd, Denmark, submitted a supplemental application to the FDA for including data from the two SWITCH phase IIIb trials in the label for diabetes drug Tresiba (insulin degludec), first approved about a year ago. The studies compared the efficacy of Tresiba vs. insulin glargine, and Tresiba turned up noninferior in reducing HbA1c.